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We investigated effects of blockade of cardiac ATP-sensitive potassium channels (KATP) with a novel cardioselective sulfonylthiourea,
HMR 1098, on metabolic uncoupling caused by a potent KATP opener, P-1075, in Langendorff-perfused rat hearts. We used (1)
87Rb-NMR to
detect activation–deactivation of sarcolemmal KATP, (2)
31P-NMR to monitor high-energy phosphates, (3) oxygen uptake measurements to
monitor cellular respiration, and (4) myocardial optical absorbance measurements at 603 nm to follow changes in cytochrome c oxidase
redox state. Activation of sarcolemmal KATP by P-1075 (5 AM) and a mitochondrial uncoupler 2,4-dinitrophenol (DNP) (50 AM) stimulated
Rb+ efflux from the hearts by 130% and 60%, respectively. HMR 1098 (5 and 30 AM) blocked activation of sarcolemmal KATP in situ. HMR
1098 also prevented cardiac arrest and mitochondrial uncoupling induced by P-1075, such as (a) depletion of phosphocreatine and ATP by
40%, (b) two-fold decrease in venous oxygen, and (c) reduction of cytochrome c oxidase (demonstrated by an increase in 603 nm optical
absorbance). The metabolic effects of P-1075 can be readily explained by activation of putative mitochondrial KATP. We concluded that
blockade of mitochondrial uncoupling by HMR 1098 included an inhibiting effect of HMR 1098 on sarcolemmal and mitochondrial KATP in
beating rat hearts.D 2003 Elsevier Science B.V. All rights reserved.Keywords: ATP-sensitive potassium channel; Oxidative phosphorylation; Oxygen consumption; Cytochrome c oxidase; NMR; Optical spectroscopy
1. Introduction lemmal K is known to protect against ischemia-inducedATP-sensitive potassium channels (KATP) are present in
plasma membrane of a variety of cell types, where the
channels serve as metabolic sensors, converting metabolic
changes to changes in ionic fluxes and regulating sarcolem-
mal membrane excitability [1]. A second type of KATP,
mitochondrial, is present in the inner mitochondrial mem-
brane and is involved in the regulation of mitochondrial
membrane potential (DC) [2]. Blockade of cardiac sarco-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00078-4
Abbreviations: DNP, 2,4-dinitrophenol; HR, heart rate; KATP, ATP-
sensitive potassium channels; KHB, Krebs–Henseleit buffer; LVEDP, left
ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure;
PP, perfusion pressure
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fibrillation [3,4], while short-term activation of the mito-
chondrial KATP has been proposed to protect cardiac ener-
getics and function during subsequent long-term ischemia
[5,6]. Recently, Aventis Pharma, Frankfurt, Germany, syn-
thesized a novel cardioselective KATP inhibitor, HMR 1098
(a free acid form, HMR 1883) [4]. This drug is a derivative of
a well-known KATP inhibitor, glibenclamide that effectively
blocks all types of KATP [2,3,6]. The non-aromatic substitu-
tions in the sulfonylurea moiety greatly increased cardiose-
lectivity of the drug and reduced the overall blocking
potency, in comparison to glibenclamide [4,7]. In animal
models, HMR 1098 exerted cardiodepressant effects, de-
creasing the incidences of ventricular tachycardia and ven-
tricular fibrillation [4,8]. Based on measurements of
flavoprotein fluorescence in isolated rabbit cardiomyocytes,
it has been proposed that HMR 1098 lacks the ability to
block mitochondrial KATP [9,10].ed.
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derivative of pinacidil [11]), provided clear evidence that
strong activation of KATP in intact beating rat hearts results in
uncoupling of oxidative phosphorylation [12]. This effect
was attributed to activation of mitochondrial KATP, because
opening of sarcolemmal KATP per se has a cardioplegic
effect, whereas opening of mitochondrial channels, depend-
ing on the degree of activation, may lead to depolarization of
mitochondrial membrane, dissipation of DC, and a decrease
in ATP production [12–15]. This makes P-1075 a very
useful probe for testing the effects of other modulators of
mitochondrial KATP in situ. In the present study, we intended
to block sarcolemmal KATP in Langendorff-perfused rat
hearts, using HMR 1098, and to investigate the effect of
the blockade on P-1075-induced mitochondrial uncoupling.
Unexpectedly, HMR 1098 blocked all mitochondrial effects
of P-1075.2. Materials and methods
The investigation conforms with the ‘‘Guide to the Care
and Use of Experimental Animals’’ published by the Cana-
dian Council on Animal Care (2nd edition, Ottawa, ON,
1993).
2.1. Reagents
Dimethylsulfoxide, 2,4-dinitrophenol (DNP), and RbCl
were purchased from Sigma (St. Louis, MO, USA). P-1075
was synthesized in Bristol-Myers Squibb (BMS) Pharma-
ceutical Research Institute laboratories to be used for internal
and collaborative use by BMS. HMR 1098 was a kind gift
from Aventis Pharma. All other chemicals were of analytical
grade. Stock solutions P-1075 were prepared in dimethyl-
sulfoxide and further diluted in water. HMR 1098 was
dissolved in water.
2.2. Heart perfusion
Male Sprague–Dawley rats (320–370 g) were anesthe-
tized with pentobarbital solution (120 mg/kg). The hearts
(1.4–1.7 g) were quickly removed and perfused retrogradely
with phosphate-free KHB containing (in mM): 25 NaHCO3,
118 NaCl, 4.7 KCl, 1.75 CaCl2, 1.2 MgSO4, 0.5 EDTA, and
11 glucose aerated with a mixture of 95% O2 and 5% CO2 to
keep pO2 at 500–600 mm Hg and pH at 7.4 at 36 jC. KHB-
Rb had the same composition as KHB, except for K+, which
was substituted with Rb+ by 50%.
Following the placement of a left ventricular apical drain,
a latex balloon was inserted through the mitral valve into the
left ventricular cavity and filled with H2O (40–50 Al). The
balloon was connected to a Statham P23Db pressure trans-
ducer and to a Digi-Med Model-210 heart performance
analyzer (Micro-Med, Louisville, KY, USA) to monitor heart
rate (HR), left ventricular systolic pressure (LVSP), leftventricular end-diastolic pressure (LVEDP), and perfusion
pressure (PP). Pressure-rate product (PRP), calculated as
developed pressure (LVSP minus LVEDP) multiplied by
HR, was used as an index of mechanical work. The coronary
flow rate was monitored using an ultrasonic blood flow
meter (Transonic Systems Inc., Ithaca, NY, USA), and PP
was measured continuously through the catheter connecting
the aortic line and the second pressure transducer. Following
a stabilization period, the hearts were perfused at a constant
flow of 13–15 ml/min to provide the desired concentration
of drugs during infusion.
2.3. Experimental protocols
In 31P-NMR experiments, three initial 4-min 31P spectra
were acquired and used as a baseline. After that, P-1075 (5
AM) and HMR 1098 (5 or 30 AM) were infused for 20 min
(five 4-min 31P-NMR spectra), followed by a 16-min recov-
ery period (four additional 31P-NMR spectra). In 87Rb-NMR
experiments, initially all the hearts were loaded with Rb+ by
perfusing with KHB-Rb for 30 min. Rb+ efflux was initiated
by switching to a Rb+-free KHB. Drug infusion started
following a 4-min extracellular Rb+-washout period and
continued for an additional 20 min. In optical and oxygen
consumption experiments, baseline values were measured
for 12 min, followed by drug (P-1075, 5 AM, in the presence
or absence of HMR 1098, 5 AM) infusion for 20 min, and 16-
min recovery.
2.4. NMR spectroscopy
NMR experiments were performed using a Bruker AM-
360 WB spectrometer equipped with a 20-mm Morris
Instruments broadband probe placed in a wide bore vertical
8.4 T magnet. The 23Na signal (95.25 MHz) from the heart
and surrounding bath was used for adjusting homogeneity
(shimming) of the magnetic field. 31P-NMR spectra were
acquired at 145.8 MHz using a 24-As pulse length (60j flip
angle), 2.0 s recycle time and 4 min resolution time. The
sweep width was 10 kHz, memory size, 4 K data points, line
broadening factor, 20 Hz. After baseline correction (spline),
the heights and chemical shifts of the peaks of inorganic
phosphate (Pi), phosphocreatine (PCr), and h- and g-phos-
phate of ATP were measured using a peak-picking subrou-
tine (Bruker). The heights of the peaks prior to the drug
infusion were taken as 100%. A capillary containing 10 Al
of 1 M solution of phenylphosphonic acid was used as a
reference.
87Rb-NMR spectra were acquired at 117.8 MHz every 2
min using a spectral sweep width of 18 kHz, a recycle time of
10 ms, and a pulse duration of 55 As (90j flip angle).
Memory size was 512 data points. Line broadening factor
was 150 Hz. To minimize the signal from the extracardiac
87Rb, a suction line was placed at the bottom of the NMR
tube. A 10-Al capillary containing 1 M RbCl and 5 M KI was
used as a reference.
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A Rb+ efflux rate constant (k) was calculated as a slope
from a linear portion of a semilogarithmic plot (natural
logarithm of Rb+ peak intensity, a.u., vs. time, min) using a
linear regression method in a Microsoft Excel program.
2.6. Oxygen consumption
An aliquot of the perfusate entering the heart was taken as
an arterial sample. Venous effluent was collected from the
cannulated right atrium. The oxygen content (pO2, mm Hg)
in the samples was measured at approximately 7-min inter-
vals using Novastatprofile-Plus-9 (Nova Biomedical, MA,
USA).
2.7. Myocardial optical absorbance
Optical absorbance was measured using InfraSpec Der-
mal System manufactured by the Institute for Biodiagnos-
tics, National Research Council of Canada (Winnipeg, MB,
Canada) equipped with a custom-made bifurcated fiber-optic
cable. One end of the cable was connected to a source of
white light (Fiber Optic Illuminator, model 77501, Oriel
Instruments, Stratford, CT, USA), while a second end
terminated at the detector. The individual fibers of the cable
were combined into a common probe tip that was in a direct
contact with the left ventricle. Non-gated spectra were
acquired in the range 400–1000 nm every 30 s (60 scans).
Spectral data were processed using Grams/32, Version 4.11
computer program (Galactic Industries Corp., USA).
2.8. Statistics
ANOVA (single factor) was used for data comparison.
Differences were considered statistically significant when
P < 0.05. Data are presented as meansF standard errors.
O. Jilkina et al. / Biochimica et BFig. 1. Blockade by HMR 1098 of P-1075-induced activation of Rb efflux
in perfused rat hearts. (A) Representative 87Rb-NMR spectra illustrating
activated Rb+ efflux from a perfused rat heart treated with P-1075 (5 AM)
and reversal of the effect with HMR 1098 (5 AM). The hearts were loaded
with Rb+ as described under Materials and methods, and Rb+-washout was
initiated at time zero. Drug infusion started after the washout of extracardiac
and extracellular Rb+ (4 min of the Rb+ washout). (B) Pooled data for 87Rb
NMR experiments. Data are presented as semilogarithmic plots and straight
lines are linear fits for the data for control (n= 3), P-1075 (5 AM, n= 4)-,
and P-1075 (5 AM)+HMR 1098 (5 AM, n= 4)-treated hearts.3. Results
3.1. Blockade by HMR 1098 of P-1075-induced activation
of sarcolemmal KATP
Addition of P-1075 (5 AM) to the perfusate resulted in a
cardiac arrest due to, perhaps, plasma membrane hyper-
polarization induced by activation of sarcolemmal KATP in
sinoatrial node. P-1075 increased the rate of Rb+ efflux from
Rb+-loaded hearts more than two-fold: from k = 0.040F
0.001 under basal conditions (n = 3) to 0.093F 0.001
(n = 4), min 1. Simultaneous infusion of a cardioselective
glibenclamide analog, HMR 1098 (5 AM) prevented cardiac
arrest and abolished the Rb+ efflux increase: k = 0.046F
0.002, min 1 (n = 3) (Fig. 1). These data are consistent with
activation of sarcolemmal KATP by P-1075 and their inhib-
ition by HMR 1098 in cardiomyocytes in situ. HMR 1098alone (5 AM) had no effect on the rate of Rb+ efflux:
k = 0.045F 0.002, min 1 (n = 3), which indicates the closed
state of sarcolemmal KATP under normal conditions. HMR
1098 also fully blocked the Rb+ efflux increase due to an
indirect activation of sarcolemmal KATP by a mitochondrial
uncoupler, DNP (via a decrease in the [ATP]/[ADP] ratio).
DNP (50 AM) increased k to 0.065F 0.002, min 1 (n = 3),
while HMR 1098 (30 AM) returned the Rb+ efflux to the
basal level: k = 0.042F 0.006, min 1 (n= 3).
Table 1
Effects of P-1075 and HMR 1098 on high-energy phosphates
Group Treatment (20 min)
PCr (%) ATP (%)
Control (n= 5) 93.2F 2.7 96.6F 3.9
P-1075, 5 AM (n= 7) 60.3F 2.2* 59.7F 4.6*
HMR 1098, 5 AM (n= 3) 100.9F 2.2 94.2F 2.7
HMR 1098, 30 AM (n= 3) 76.5F 6.9* 93.2F 2.5
P-1075, 5 AM, +HMR 1098, 5 AM (n= 4) 91.1F 5.9 94.1F 4.1
P-1075, 5 AM, +HMR 1098, 30 AM (n= 4) 88.6F 6.8 91.7F 6.5
PCr and ATP levels before any interventions were set as 100%.
MeanF S.E. are presented.
*Statistically significant vs. control.
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of high-energy phosphates
The primary rationale for these experiments was to
compare the proposed sarcolemmal specificity of HMR
1098 to its parent compound, glibenclamide. In addition to
activation sarcolemmal KATP, in Langendorff-perfused beat-
ing rat hearts, P-1075, at a concentration of 5 AM, induced
mitochondrial uncoupling [12]. Infusion of HMR 1098
prevented a 40% depletion of PCr and ATP and a two-fold
increase in Pi (Fig. 2 and Table 1). Interaction of HMR 1098
with the SUR subunit of sarcolemmal KATP was reported to
be markedly (7- to 100-fold) weaker in comparison to its
parent compound, glibenclamide [16]. Glibenclamide (5
AM) was effective in blocking P-1075-induced mitochon-
drial effects in situ [12], thus initially HMR 1098 was used at
a concentration of 30 AM. However, 30 AM HMR slightly,
but significantly, decreased the level of PCr upon treatment
(Table 1), probably due to an uncoupling effect of this
compound at a high concentration, similar to that of gliben-
clamide [17]. Therefore, a lower (5 AM) concentration of
HMR 1098 was tested as well. As summarized in Table 1,
not only 30, but also 5 AM was a sufficient concentration of
HMR 1098 in preventing depletion of high-energy phos-
phates. HMR 1098 alone (5 AM) had no significant effect on
cardiac energetics (Table 1).
3.3. Effects of HMR 1098 on oxygen consumption
In another series of experiments, oxygen consumption by
the hearts was measured, under constant flow conditions. On
P-1075 treatment, oxygen concentration in venous effluent
O. Jilkina et al. / Biochimica et B124Fig. 2. Blockade by HMR 1098 of P-1075-induced changes in high-energy phosp
treated with P-1075 (5 AM) in the absence (panel A) or presence of HMR 1098 (5 A
periods before (baseline), 20-min after drug infusion, and 16-min after recovery. C
peak, which is set at zero. Pi, inorganic phosphate.reversibly decreased two-fold (Fig. 3), indicating that mito-
chondrial uncoupling rather then inhibition of electron trans-
port was the cause of ATP depletion [12]. Stimulation of
cellular respiration persisted until the removal of P-1075 (not
shown). Consistent with the results of 31P-NMR experi-
ments, HMR 1098 eliminated the P-1075-induced increase
in heart’s oxygen consumption (Fig. 3).
3.4. Effect of HMR 1098 on a P-1075-induced reduction of
cytochrome c oxidase
Simultaneous with the oxygen consumption measure-
ments, myocardial absorbance data were acquired. Absorb-
ance at 603 nm was measured as an index of cytochrome c
oxidase (cyt aa3) redox state [18]. On P-1075 treatment,
cytochrome c oxidase became reduced: a reversible transi-
tory increase was observed in the absorbance at 603 nm, but
not at other wavelengths (Fig. 4A). On average, a change inhates in perfused rat hearts. Representative 31P-NMR spectra of the hearts
M, panel B). The spectra are a sum of 116 acquisitions collected over 4-min
hemical shifts are given with reference to that of the phosphocreatine (PCr)
Fig. 3. The effects P-1075 (5 AM, n= 3) on venous oxygen pressure in the
absence and in the presence of HMR 1098 (5 AM, n= 3), in perfused rat
hearts. Venous effluent was collected from the cannulated right atrium and
oxygen content measured before (control), after 20-min drug infusion
(treatment), and after 16-min recovery.
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(n = 3), in comparison to that induced by global no-flow
ischemia (Fig. 4A). The effect of P-1075 was also fully
blocked by HMR 1098 (Fig. 4B).Fig. 4. Effect of P-1075 (in the absence or presence of HMR 1098) on cytochrome
and 650 nm (bottom trace) from a representative heart treated with P-1075. P-107
was subjected to global no-flow ischemia between 50 and 55 min of the protoc
indicative of the redox state of cytochrome c oxidase. Absorbance at 650 nm was ch
Pooled data for the hearts treated with P-1075 (5 AM, n= 3) and P-1075 (5 AM)+
group vs. ‘‘P-1075 +HMR 1098’’ group. (C) Pooled data for the hearts treated wit
the changes caused by DNP.In comparison, 50 AM DNP induced a similar 603 nm
absorbance increase (Fig. 4C). However, the kinetics was
different: while the change in 603 nm absorbance induced by
P-1075 was transitory and cytochrome c oxidase redox state
returned to the basal level before the P-1075 washout, on
DNP application (20 min), cytochrome c oxidase remained
reduced until the removal of DNP (Fig. 4C). DNP-induced
603 nm absorbance change was 37.9F 5.8% (n = 3) of that
induced by ischemia.
3.5. Mechanical function of Langendorff-perfused rat
hearts on drug treatment
There were no significant differences in the baseline
parameters of hearts in all groups: typically, HR was approx-
imately 275 beats/min; LVEDP 7, LVSP 110, and PP 70 mm
Hg. Addition of 5 AM P-1075 resulted in cardiac arrest (after
approximately 9 min). During 20-min treatment, P-1075
caused a marked increase in LVEDP (Fig. 5A) and a decrease
in LVSP (Fig. 5B); systolic and diastolic pressures became
equal following cardiac arrest. The effects on LVSP and
LVEDP were significantly attenuated by the infusion ofc oxidase redox state. (A) Time course of the absorbance at 603 (top trace)
5 (5 AM) was infused between 20 and 40 min of the experiment. The heart
ol to calibrate the changes caused by P-1075. Absorbance at 603 nm was
osen to demonstrate non-specific changes in the heart optical properties. (B)
HMR 1098 (5 AM, n= 3). P< 0.05 is indicated for data in ‘‘P-1075-only’’
h DNP (50 AM, n= 3) and subjected to global no-flow ischemia to calibrate
Fig. 5. Summarized data on left ventricular end-diastolic and systolic
pressures of hearts treated with P-1075 (5 AM) and HMR 1098. The hearts
were treated for 20 min with the HMR 1098 at indicated concentrations and
the values correspond to 20 min of drug treatment.
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5). HMR 1098 alone (30 AM) slightly, but statistically
significantly, increased LVEDP; however, 5 AM had no
effect (Fig. 5A).4. Discussion
To investigate cardiac effects of HMR 1098 in situ, we
used a combination of non-invasive methods, namely: (1)
87Rb-NMR spectroscopy to detect activation–deactivation
of sarcolemmal KATP, (2)
31P-NMR spectroscopy to monitor
high-energy phosphates, (3) oxygen uptake measurements to
monitor cellular respiration, and (4) myocardial optical
absorbance at 603 nm to follow changes in cytochrome c
oxidase redox state [12,18,19]. The results of all these
experiments clearly demonstrated that HMR 1098 blocks
not only sarcolemmal, but also mitochondrial effects induced
by a KATP opener, P-1075, in the hearts.
In addition to already established effects of P-1075 on
high-energy phosphates, oxygen uptake, and contractile
parameters [12], this drug also caused transient reductionof cytochrome c oxidase. This is consistent with mitochon-
drial uncoupling, which facilitates faster movement of redox
equivalents to cytochrome c oxidase causing its reduction.
Return of the redox state to the baseline prior to P-1075
washout (Fig. 4) probably reflects changes in the kinetic
properties of cytochrome c oxidase and Krebs cycle in a
response to the [ATP]/[ADP] decrease, [Pi] and [H
+]
increases, mitochondrial swelling [20], as well as changes
in some unknown factors, triggered by cardiac arrest. For
example, inhibition of Krebs cycle and/or dehydrogenases
would reoxidize cytochrome c oxidase.
The observation that P-1075 binds with high affinity to
myocardial membrane preparations (containing sarcolemmal
and mitochondrial membranes) in MgATP-dependent and
glibenclamide-sensitive manner [21], provides evidence for
the interaction of P-1075 with native cardiac KATP. There is
no doubt that P-1075 interacts with native sarcolemmal KATP.
P-1075 is the only KATP opener, whose significant phar-
macological binding to recombinant sarcolemmal KATP was
demonstrated [22,23]. However, interaction of P-1075 with
native mitochondrial KATP has not been demonstrated dir-
ectly. Moreover, up to date, the molecular identity of mito-
chondrial KATP has not been established. The existence of
glibenclamide-sensitive mitochondrial KATP was suggested
based on (a) patch–clamp experiments on fused mitoplasts
[2], (b) measurements of K+ fluxes through mitochondrial
channel fraction reconstituted in lipid membranes [24], (c)
mitochondrial swelling [20] and (d) pharmacological studies
involving presumably specific mitochondrial KATP modula-
tors, diazoxide and 5-hydroxydecanoate (5-HD) [5,6]. In
addition, uncoupling induced by several KATP openers in
isolated mitochondria [13,15] and quiescent rabbit cardio-
myocytes was attributed to the activation of mitochondria
KATP [14]. Recently, however, non-channel metabolic effects
of diazoxide and 5-HD were demonstrated [25,26]. More-
over, the validity of the models allowing indirect measure-
ments of mitochondrial KATP activity was questioned [27–
30], thus, further signifying that until these channels are
identified at the molecular level, interpretation of the data
leaves room for discussion. Nevertheless, glibenclamide
binding to mitochondria provides another indirect evidence
for the existence of mitochondrial KATP [31], since highly
specific interaction of glibenclamide with the sulfonylurea
receptor of KATP is well established [3,6].
Unlike DNP-induced uncoupling of oxidative phosphor-
ylation, uncoupling by P-1075 was completely inhibited by
glibenclamide [12] and HMR 1098 (this work), which clearly
indicated involvement of KATP, either mitochondrial or
sarcolemmal. One cannot completely discard the possibility
that activation of sarcolemmal KATP could contribute towards
the metabolic effects of P-1075 via generation of an ‘‘uncou-
pling factor.’’ The missing link in this hypothesis is the nature
and mechanism of generation of the factor. Elevated cyto-
plasmic Ca+ + (entered through sarcolemma or released from
sarcoplasmic reticulum) and/or free fatty acids (due to
activation of lipolysis of endogenous lipids) can impair
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that likely resulted from activation of sarcolemmal KATP by
P-1075, would rather decrease Ca+ + entry [32], and there is
no data to suggest KATP openers-dependent Ca
+ + release
from sarcoplasmic reticulum, or lipolysis. For these reasons,
activation of putative mitochondrial KATP by P-1075 and
depolarization of mitochondrial membrane seems to be a
more plausible hypothesis. Blockade of the P-1075 metabolic
effects by the sulfonylureas also demonstrated that at the
concentration used in this study, any possible non-KATP
effects of P-1075 on cardiac metabolism were negligible.
Sarcolemmal specificity of HMR 1098 was initially pro-
posed, based on the measurements of mitochondrial flavo-
protein fluorescence in isolated quiescent rabbit cardiomyo-
cytes [9]. It was demonstrated that HMR 1098 did not affect
diazoxide- and pinacidil-induced flavoprotein oxidation in
these cells [9,10]. However, it has to be noted that the same
model did not allow measurements of a well-established
effect of glibenclamide [2] on mitochondrial KATP [9,10]
and, thus, may not detect the effect of a related drug, HMR
1098. In addition, ability of HMR 1098 to block a KATP
opener-induced mitochondrial uncoupling may be different
in quiescent rabbit cardiomyocytes and beating rat hearts due
to a different energetic status ([ATP]/[ADP] ratio), Ca+ +
levels, and/or other presently unknown factors. Indeed,
state-dependent effects of glibenclamide on mitochondrial
KATP were reported [33]. Finally, flavoprotein fluorescence
[9,10] and high-energy phosphates (Ref. [12] and this work)
may respond differently to treatment with KATP effectors
(e.g., glibenclamide and P-1075). It was reported also that in
lipid bilayers containing phosphatidylethanolamine and
phosphatidylserine, reconstituted mitochondrial KATP could
not be blocked with HMR 1098 [34]. However, this model
did not include cardiolipin, which is the only phospholipid
localized exclusively in mammalian mitochondria and
involved in the modulation of a number of mitochondrial
functions [35].
Additional evidence to support sarcolemmal specificity of
HMR 1098 comes from the studies of ischemic and pharma-
cological preconditioning, the phenomenon presumably
involving mitochondrial KATP [5,6]. However, precondition-
ing experiments do not provide direct measurement of
mitochondrial KATP activity. In addition, these studies are
ambiguous, as contradictory results have been reported.
Several researchers observed no effect of HMR 1098 on
different types of preconditioning [36–42]. However, others
demonstrated that HMR 1098, attenuated or blocked pro-
tection by ischemic, KATP-opener- or isoflurane-induced
myocardial preconditioning in rabbits [43–45], desflurane-
induced cardioprotection in dogs [46], and delayed opioid-
induced preconditioning in rats [47], raising doubts that
HMR 1098 blocks only sarcolemmal KATP. Alternatively,
these reports leave room for the interpretation of the results,
as to whether not only mitochondrial, but also sarcolemmal
KATP are involved in a variety of types of preconditioning.
Interestingly, Suzuki et al. [48] demonstrated the absence ofischemic preconditioning in Kir6.2 /  transgenic mice
lacking sarcolemmal, but not mitochondrial KATP, thus,
further signifying the role of sarcolemmal membrane proper-
ties in cardioprotection. This group proposed the phenom-
enon to be typical of mice, whose heart rate is high (f 600
beats/min), however, sarcolemmal KATP may play a crucial
role in cardioprotection of other species.
In summary it was demonstrated that HMR 1098 blocks
mitochondrial uncoupling by P-1075, assessed by depletion
of PCr and ATP, decreased venous oxygen, and reduction of
cytochrome c oxidase in Langendorff-perfused rat hearts.Acknowledgements
This project was supported, in part, by Canadian
Institutes of Health Research (CIHR) through a grant
MOP-42626 to V.K.References
[1] A. Noma, ATP-regulated K+ channels in cardiac muscle, Nature 305
(1983) 147–148.
[2] I. Inoue, H. Nagase, K. Kishi, T. Higuti, ATP-sensitive K+ channel in
the mitochondrial inner membrane, Nature 352 (1991) 244–247.
[3] G. Edwards, A.H. Weston, The pharmacology of ATP-sensitive potas-
sium channels, Annu. Rev. Pharmacol. Toxicol. 33 (1993) 597–637.
[4] H. Go¨gelein, J. Hartung, H.C. Englert, B.A. Scho¨lkens, HMR 1883, a
novel cardioselective inhibitor of the ATP-sensitive potassium chan-
nel: Part I. Effects on cardiomyocytes, coronary flow and pancreatic
h-cells, J. Pharmacol. Exp. Ther. 286 (1998) 1453–1464.
[5] G.J. Gross, R.M. Fryer, Sarcolemmal versus mitochondrial ATP-sen-
sitive K+ channels and myocardial preconditioning, Circ. Res. 84
(1999) 973–979.
[6] G.J. Grover, K.D. Garlid, ATP-sensitive potassium channels: a review
of their cardioprotective pharmacology, J. Mol. Cell. Cardiol. 32
(2000) 677–695.
[7] J.E. Manning Fox, H.D. Kanji, R.J. French, P.E. Light, Cardioselec-
tivity of the sulphonylurea HMR 1098: studies on native and recombi-
nant cardiac and pancreatic KATP channels, Br. J. Pharmacol. 135
(2002) 480–488.
[8] H. Go¨gelein, H. Ruetten, U. Albus, H.C. Englert, A.E. Busch, Effects
of the cardioselective KATP channel blocker HMR 1098 on cardiac
function in isolated perfused working rat hearts and in anesthetized
rats during ischemia and reperfusion, Naunyn-Schmiedeberg’s Arch.
Pharmacol. 364 (2001) 33–41.
[9] T. Sato, N. Sasaki, J. Seharaseyon, B. O’Rourke, E. Marban, Selective
pharmacological agents implicate mitochondrial, but not sarcolemmal
KATP channels in ischemic cardioprotection, Circulation 101 (2000)
2418–2423.
[10] Y. Liu, G. Ren, B. O’Rourke, E. Marban, J. Seharaseyon, Pharmaco-
logical comparison of native mitochondrial KATP channels with mo-
lecularly defined surface KATP channels, Mol. Pharmacol. 59 (2001)
225–230.
[11] J.K. Smallwood, M.I. Steinberg, Cardiac electrophysiological effects
of pinacidil and related pyridylcyanoguanidines: relationship to anti-
hypertensive activity, J. Cardiovasc. Pharmacol. 12 (1988) 102–109.
[12] O. Jilkina, B. Kuzio, G.J. Grover, V.V. Kupriyanov, Effects of KATP
channel openers, P-1075, pinacidil, and diazoxide, on energetics and
contractile function in isolated rat hearts, J. Mol. Cell. Cardiol. 34
(2002) 427–440.
O. Jilkina et al. / Biochimica et Biophysica Acta 1638 (2003) 121–128128[13] A. Szewczyk, G. Wojcik, M.J. Nalecz, Potassium channel opener, RP
66471, induces membrane depolarization of rat liver mitochondria,
Biochem. Biophys. Res. Commun. 207 (1995) 126–132.
[14] T. Sato, B. O’Rourke, E. Marban, Modulation of mitochondrial ATP-
dependent K+ channels by protein kinase C, Circ. Res. 83 (1998)
110–114.
[15] E.L. Holmuhamedov, S. Jovanovic, P.P. Dzeja, A. Jovanovic, A.
Terzic, Mitochondrial ATP-sensitive K+ channels modulate cardiac
mitochondrial function, Am. J. Physiol. 275 (1998) H1567–H1576.
[16] U. Russ, U. Lange, C. Lo¨ffler-Walz, A. Hambrock, U. Quast, Inter-
action of the sulfonylthiourea HMR 1833 with sulfonylurea receptors
and recombinant ATP-sensitive K+ channels: comparison with gliben-
clamide, J. Pharmacol. Exp. Ther. 299 (2001) 1049–1055.
[17] A. Czewczyk, A. Czyz, M.J. Nalecz, ATP-regulated potassium chan-
nel blocker, glibenclamide, uncouples mitochondria, Pol. J. Pharma-
col. 49 (1997) 49–52.
[18] F.W. Heineman, V.V. Kupriyanov, R. Marshall, T.A. Fralix, R.S. Ba-
laban, Myocardial oxygenation in the isolated working rabbit heart as
a function of work, Am. J. Physiol. 262 (1992) H255–H267.
[19] V.V. Kupriyanov, E. Yushmanov, B. Xiang, R. Deslauriers, Kinetics
of ATP-sensitive K+ channels in isolated rat hearts assessed by 87Rb
NMR spectroscopy, NMR Biomed. 11 (1998) 131–140.
[20] A.D. Beavis, Y. Lu, K.D. Garlid, On the regulation of K+ uniport in
intact mitochondria by adenine nucleotides and nucleotide analogs,
J. Biol. Chem. 268 (1993) 997–1004.
[21] K.S. Atwal, G.J. Grover, N.J. Lodge, D.E. Normandin, S.C. Traeger,
P.G. Sleph, R.B. Cohen, C.C. Bryson, K.E.J. Dickinson, Binding of
ATP-sensitive potassium channel (KATP) openers to cardiac mem-
branes: correlation of binding affinities with cardioprotective and
smooth muscle relaxing potencies, J. Med. Chem. 41 (1998) 271–275.
[22] M. Schwanstecher, C. Sieverding, H. Do¨rschner, I. Gross, L. Aguilar-
Bryan, C. Schwanstecher, J. Bryan, Potassium channel openers re-
quire ATP to bind to and act through sulfonylurea receptors, EMBO J.
17 (1998) 5529–5535.
[23] A. Hambrock, C. Lo¨ffler-Walz, D. Kloor, U. Delabar, Y. Horio, Y.
Kurachi, U. Quast, ATP-sensitive K+ channel modulator binding
to sulfonylurea receptors SUR2A and SUR2B: opposite effects of
MgADP, Mol. Pharmacol. 55 (1999) 832–840.
[24] P. Paucek, G. Mironova, F. Mahdi, A.D. Beavis, G. Woldegiorgis,
K.D. Garlid, Reconstitution and partial purification of the glibencla-
mide-sensitive, ATP-dependent K+ channel from rat liver and beef
heart mitochondria, J. Biol. Chem. 267 (1992) 26062–26069.
[25] P.J. Hanley, M. Mickel, M. Lo¨ffler, U. Brandt, J. Daut, KATP channel-
independent targets of diazoxide and 5-hydroxydecanoate in the heart,
J. Physiol. 542 (2002) 735–741.
[26] K.H.H. Lim, S.A. Javadov, M. Das, S.J. Clarke, M.-S. Suleiman, A.P.
Halestrap, The effects of ischaemic preconditioning, diazoxide and 5-
hydroxydecanoate on rat heart mitochondrial volume and respiration,
J. Physiol. 545 (2002) 961–974.
[27] K.D. Garlid, Opening mitochondrial KATP in the heart—what happens,
and what does not happen, Basic Res. Cardiol. 95 (2000) 275–279.
[28] A.J. Kowaltowski, S. Seetharaman, P. Paucek, K.D. Garlid, Bioener-
getic consequences of opening the ATP-sensitive K+ channel of heart
mitochondria, Am. J. Physiol. 280 (2001) H649–H657.
[29] C.L. Lawrence, B. Billups, G.C. Rodrigo, N.B. Standen, The KATP
channel opener diazoxide protects cardiac myocytes during metabolic
inhibition without causing mitochondrial depolarization or flavopro-
tein oxidation, Br. J. Physiol. 134 (2001) 535–542.
[30] M. Das, J.E. Parker, A.P. Halestrap, Matrix volume measurements
challenge the existence of diazoxide/glibenclamide-sensitive KATP
channels in rat mitochondria, J. Physiol. 547 (2003) 893–902.
[31] A. Szewczyk, G. Wojcik, N.A. Lobanov, M.J. Nalecz, The mitochon-
drial sulfonylurea receptor: identification and characterization, Bio-
chem. Biophys. Res. Commun. 230 (1997) 611–615.[32] N.M. Cohen, R.J. Damiano Jr., A.S. Wechsler, Is there an alternative
to potassium arrest? Ann. Thorac. Surg. 60 (1995) 858–863.
[33] M. Jaburek, V. Yarov-Yarovoy, P. Paucek, K.D. Garlid, State-depend-
ent inhibition of the mitochondrial KATP channel by glyburide and 5-
hydroxydecanoate, J. Biol. Chem. 273 (1998) 13578–13582.
[34] D.X. Zhang, Y.-F. Chen, W.B. Campbell, A.-P. Zou, G.J. Gross, P.-L.
Li, Characteristics and superoxide-induced activation of reconstituted
myocardial mitochondrial ATP-sensitive potassium channels, Circ.
Res. 89 (2001) 1177–1183.
[35] G.M. Hatch, Cardiolipin: biosynthesis, remodeling and trafficking in
the heart and mammalian cells (review), Int. J. Mol. Med. 1 (1998)
33–41.
[36] R.M. Fryer, A.K. Hsu, H. Nagase, G.J. Gross, Opioid-induced
cardioprotection against myocardial infarction and arrhythmias: mi-
tochondrial versus sarcolemmal ATP-sensitive potassium channels,
J. Pharmacol. Exp. Ther. 294 (2000) 451–457.
[37] T. Sato, N. Sasaki, B. O’Rourke, E. Marban, Nicorandil, a potent
cardioprotective agent, acts by opening mitochondrial ATP-dependent
potassium channels, J. Am. Coll. Cardiol. 35 (2000) 514–518.
[38] Y. Toyoda, S. Levitsky, J.D. McCully, Opening of mitochondrial
ATP-sensitive potassium channels enhances cardioplegic protection,
Ann. Thorac. Surg. 71 (2001) 1281–1289.
[39] S. Ghosh, N.B. Standen, M. Galinanes, Evidence for mitochondrial
KATP channels as effectors of human myocardial preconditioning,
Cardiovasc. Res. 45 (2000) 934–940.
[40] P.E. Light, H.D. Kanji, J.E. Manning Fox, R.J. French, Distinct my-
oprotective roles of cardiac sarcolemmal and mitochondrial KATP
channels during metabolic inhibition and recovery, FASEB J. 15
(2001) 2586–2594.
[41] O. Jung, H.C. Englert, W. Jung, H. Go¨gelein, B.A. Scho¨lkens, A.E.
Busch, W. Linz, The KATP channel blocker HMR 1883 does not
abolish the benefit of ischemic preconditioning on myocardial infarct
mass in anesthetized rabbits, Naunyn-Schmiedeberg’s Arch. Pharma-
col. 361 (2000) 445–451.
[42] R.M. Fryer, J.T. Eells, A.K. Hsu, M.M. Henry, G.J. Gross, Ischemic
preconditioning in rats: role of mitochondrial KATP channel in pres-
ervation of mitochondrial function, Am. J. Physiol. 278 (2000)
H305–H312.
[43] M. Tanno, T. Miura, A. Tsuchida, T. Miki, Y. Nishino, Y. Ohnuma, K.
Shimamoto, Contribution of both the sarcolemmal KATP and mito-
chondrial KATP channels to infarct size limitation by KATP channel
openers: differences from preconditioning in the role of sarcolemmal
KATP channels, Naunyn-Schmiedeberg’s Arch. Pharmacol. 364 (2001)
226–232.
[44] M. Birincioglu, X.-M. Yang, S.D. Critz, M.V. Cohen, J.M. Downey,
S–T segment voltage during sequential coronary occlusions is an
unreliable marker of preconditioning, Am. J. Physiol. 277 (1999)
H2435–H2441.
[45] M. Tonkovic-Capin, G.J. Gross, Z.J. Bosnjak, J.S. Tweddell, C.M.
Fitzpatrick, J.E. Baker, Delayed cardioprotection by isoflurane: role
of KATP channels, Am. J. Physiol. 283 (2002) H61–H68.
[46] W.G. Toller, E.R. Gross, J.R. Kersten, P.S. Pagel, G.J. Gross, D.C.
Warltier, Sarcolemmal and mitochondrial adenosine triphosphate-de-
pendent potassium channels: mechanism of desflurane-induced cardi-
oprotection, Anesthesiology 92 (2000) 1731–1739.
[47] J. Peart, H.H. Patel, A.K. Hsu, G.J. Gross, The delayed cardioprotec-
tive effect of non-peptide opioid agonists are triggered and mediated
via sarc and mito KATP channels respectively. Proceedings of the
ISHR North American Section 24th Annual Meeting, J. Mol. Cell.
Cardiol. 34 (2002) A34 (Abstract).
[48] M. Suzuki, N. Sasaki, T. Miki, N. Sakamoto, Y. Ohmoto-Sekine, M.
Tamagawa, S. Seino, E. Marban, H. Nakaya, Role of sarcolemmal
KATP channels in cardioprotection against ischemia/reperfusion injury
in mice, J. Clin. Invest. 109 (2002) 509–516.
